Cardioprotection by ischemic postconditioning and cyclic guanosine monophosphate-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase
Open Access
- 9 February 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 114 (6) , 822-829
Abstract
It has been suggested that the nitric oxide-sensitive guanylyl cyclase (NO-GC)/cyclic guanosine monophosphate (cGMP)-dependent signalling pathway affords protection against cardiac damage during acute myocardial infarction (AMI). It is, however, not clear whether the NO-GC/cGMP system confers its favourable effects through a mechanism located in cardiomyocytes (CMs). The aim of this study was to evaluate the infarct-limiting effects of the endogenous NO-GC in CMs in vivo. Ischemia/reperfusion (I/R) injury was evaluated in mice with a CM-specific deletion of NO-GC (CM NO-GC KO) and in control siblings (CM NO-GC CTR) subjected to an in vivo model of AMI. Lack of CM NO-GC resulted in a mild increase in blood pressure but did not affect basal infarct sizes after I/R. Ischemic postconditioning (iPost), administration of the phosphodiesterase-5 inhibitors sildenafil and tadalafil as well as the NO-GC activator cinaciguat significantly reduced the amount of infarction in control mice but not in CM NO-GC KO littermates. Interestingly, NS11021, an opener of the large-conductance and Ca2+-activated potassium channel (BK), an important downstream effector of cGMP/cGKI in the cardiovascular system, protects I/R-exposed hearts of CM NO-GC proficient and deficient mice. These findings demonstrate an important role of CM NO-GC for the cardioprotective signalling following AMI in vivo. CM NO-GC function is essential for the beneficial effects on infarct size elicited by iPost and pharmacological elevation of cGMP; however, lack of CM NO-GC does not seem to disrupt the cardioprotection mediated by the BK opener NS11021.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (LU 1490/3-1 and LU 1490/3-2, FR 1725/3-2)
This publication has 48 references indexed in Scilit:
- Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyondTrends in Pharmacological Sciences, 2014
- Protection through postconditioning or a mitochondria-targeted S-nitrosothiol is unaffected by cardiomyocyte-selective ablation of protein kinase GBasic Research in Cardiology, 2013
- Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfideAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in miceAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Myocardial Reperfusion InjuryNew England Journal of Medicine, 2007
- Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclaseProceedings of the National Academy of Sciences, 2007
- Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial KATP channels when administered at reperfusion following ischemia in rabbitsJournal of Molecular and Cellular Cardiology, 2007
- Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioningAmerican Journal of Physiology-Heart and Circulatory Physiology, 2003
- Major occurrence of the new α2β1 isoform of NO-sensitive guanylyl cyclase in brainCellular Signalling, 2003
- Tissue Distribution of the Human Soluble Guanylate CyclasesBiochemical and Biophysical Research Communications, 1999